Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Sorrento Therape stock

Learn how to easily invest in Sorrento Therape stock.

Sorrento Therape is a biotechnology business based in the US. Sorrento Therape shares (SRNE) are listed on the NASDAQ and all prices are listed in US Dollars. Sorrento Therape employs 799 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Sorrento Therape

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – SRNE – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Sorrento Therape stock price (NASDAQ: SRNE)

Use our graph to track the performance of SRNE stocks over time.

Sorrento Therape shares at a glance

Information last updated 2022-06-20.
Latest market close$2.07
52-week range$1.15 - $11.07
50-day moving average $1.63
200-day moving average $4.21
Wall St. target price$21.00
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.53

Buy Sorrento Therape shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
$10
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$1
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Axos Bank Self Directed Investing
Stocks
$0
$1,000
$150
when you open an account and deposit at least $1500.
Vanguard Personal Advisor
Stocks, Mutual funds, ETFs
$0
$0
N/A
Financial advice powered by relationships, not commissions.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Sorrento Therape stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Sorrento Therape price performance over time

Historical closes compared with the close of $2.07 from 2022-06-24

1 week (2022-06-17) 23.21%
1 month (2022-05-23) 31.01%
3 months (2022-03-24) -17.86%
6 months (2021-12-22) N/A
1 year (2021-06-25) -79.01%
2 years (2020-06-26) -64.74%
3 years (2019-06-26) 3.37
5 years (2017-06-26) 2.1

Sorrento Therape financials

Revenue TTM $57 million
Gross profit TTM $-167,049,000
Return on assets TTM -32.96%
Return on equity TTM -206.57%
Profit margin 0%
Book value $0.62
Market capitalisation $653.4 million

TTM: trailing 12 months

Sorrento Therape share dividends

We're not expecting Sorrento Therape to pay a dividend over the next 12 months.

Have Sorrento Therape's shares ever split?

Sorrento Therape's shares were split on a 1:25 basis on 31 July 2013. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sorrento Therape shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Sorrento Therape shares which in turn could have impacted Sorrento Therape's share price.

Sorrento Therape share price volatility

Over the last 12 months, Sorrento Therape's shares have ranged in value from as little as $1.15 up to $11.07. A popular way to gauge a stock's volatility is its "beta".

SRNE.US volatility(beta: 2.43)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sorrento Therape's is 2.4288. This would suggest that Sorrento Therape's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Sorrento Therape overview

Sorrento Therapeutics, Inc. , a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia.

Frequently asked questions

What percentage of Sorrento Therape is owned by insiders or institutions?
Currently 5.791% of Sorrento Therape shares are held by insiders and 33.595% by institutions.
How many people work for Sorrento Therape?
Latest data suggests 799 work at Sorrento Therape.
When does the fiscal year end for Sorrento Therape?
Sorrento Therape's fiscal year ends in December.
Where is Sorrento Therape based?
Sorrento Therape's address is: 4955 Directors Place, San Diego, CA, United States, 92121
What is Sorrento Therape's ISIN number?
Sorrento Therape's international securities identification number is: US83587F2020
What is Sorrento Therape's CUSIP number?
Sorrento Therape's Committee on Uniform Securities Identification Procedures number is: 74838K108

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site